Aligos Therapeutics

ALGS

Market cap $33.7M

ALGS Hedge Fund Activity: Q1 2026 in Review

35 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q1 2026, worth a combined $20.6M — down 21% from $26.2M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of ALGS and 7 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 8 added.

The largest buyer was Bank of America, adding an estimated $1.64M. The largest seller was Woodline Partners, cutting an estimated $848K.

• 35 institutional investors held Aligos Therapeutics (ALGS) as of Q1 2026, down from 40 in Q4 2025.
• Funds reported $20.6M of Aligos Therapeutics stock for Q1 2026, down 21% quarter-over-quarter.
• 7 funds opened new Aligos Therapeutics positions in Q1 2026 and 10 closed out, a net change of -3 holders.
• The largest Aligos Therapeutics buyer in Q1 2026 was Bank of America, an estimated $1.64M added.
• The largest Aligos Therapeutics seller in Q1 2026 was Woodline Partners, an estimated $848K sold.

Based on aggregated 13F filings for Q1 2026.